Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 18, 2004

View Archived Issues

Numax enters new phase III RSV study in Native American infants

New U.S. site added to phase II ProCord study for acute spinal cord injury

Tetrodin studied in phase II trial of opiate-dependent subjects

Full enrollment achieved in phase III study of Celacade for PAD

Lorus signs Virulizin supply agreement with BioVectra

Crucell highlights progress

Doxorubicin Transdrug receives European orphan drug status

Fast track status for XP-12B for menorrhagia

Australian phase II study of Testosterone MDTS completed

Raven files IND for phase I study of RAV-12 in advanced adenocarcinoma

Nesterone MDTS contraceptive spray enters clinical testing

In vitro and in vivo characterization of SLV-326, a novel cannabinoid CB1 receptor antagonist

Aldosterone synthase inhibition with FAD-286: a novel therapy for the treatment of CHF

HS-2-45: a novel anticonvulsant reported to modulate Na+ channel gating

In vitro, in vivo characterization of JNJ-17308616, a novel anxiolytic V1a receptor antagonist

Scientists at AmorePacific claim genistein for the treatment of obesity

ARS investigators describe a new use of clusterin for peripheral neurological diseases

New use of ritonavir for unconjugated hyperbilirubinemia claimed by Abbott

Vertex patent covers protein kinase inhibitors

Protein kinase modulators claimed by Exelixis

GSK-3beta inhibitors for the treatment of neurodegenerative diseases

Antiatherosclerotic effects of oral apolipoprotein A-I mimetic

Phase II data on the immunogenicity of the influenza vaccine FluBlok in elderly subjects

Preclinical profile of WAY-909, a novel selective 5-HT2C receptor selective agonist

Rosuvastatin significantly improves hypercholesterolemia in African Americans

Pexelizumab reduces mortality in patients undergoing CABG and aortic valve surgery

Antiviral effects, pharmacokinetics and safety of VX-950 in HCV infection

Update on the antitumor effects and safety of lapatinib in advanced breast cancer

Safety, distribution of ChimeriVax-West Nile vaccine assessed in monkeys

Vaxfectin enhances antimalarial plasmid DNA vaccines

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 31, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...